Slow waning of antibodies following a third dose of BNT162b2 in adults who had
previously received two doses of inactivated vaccine

Benjamin J. Cowling¹,², Samuel M. S. Cheng¹, Mario Martín-Sánchez¹, Niki Y. M. Au¹, Karl
C. K. Chan¹, John K. C. Li¹, Leo L. H. Luk¹, Leo C. H. Tsang¹, Dennis K. M. Ip¹, Leo L. M.
Poon¹,³,⁴, Gabriel M. Leung¹,², J. S. Malik Peiris†¹,³,⁴, Nancy H. L. Leung†¹,²

†Joint senior authors with equal contribution

Affiliations:
1. WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of
Public Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong Special
Administrative Region, China.
2. Laboratory of Data Discovery for Health; Hong Kong Science and Technology Park, Hong
Kong Special Administrative Region, China.
3. HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine,
The University of Hong Kong; Hong Kong Special Administrative Region, China.
4. Centre for Immunology and Infection; Hong Kong Science and Technology Park, Hong
Kong Special Administrative Region, China.

Corresponding author:
Benjamin Cowling, WHO Collaborating Centre for Infectious Disease Epidemiology and
Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong;
Hong Kong Special Administrative Region, China. becowling@hku.hk

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Running head: Robust immunity after BNT162b2 booster

Word count (abstract): 250

Word count (main text): 2175
**ABSTRACT**

**Introduction:** Third doses of COVID-19 vaccination provide an important boost to immunity, reducing the risk of symptomatic infection and the risk of severe disease. Third doses have been particularly important for improving protection against variants. However, waning of clinical protection particularly against Omicron has been noted after receipt of third doses.

**Methods:** We administered BNT162b2 as a third dose to adults aged ≥30 years who had previously received two doses of inactivated vaccination. We collected blood before the third dose and again after one month and six months, and tested sera using a spike receptor binding domain IgG enzyme-linked immunosorbent assay, a surrogate virus neutralization test, and live virus plaque reduction neutralization assay against ancestral virus and Omicron BA.2.

**Results:** We administered BNT162b2 as a third dose to 314 adults. We found robust antibody responses to the ancestral strain at six months after receipt of BNT162b2. Antibody responses to Omicron BA.2 were weaker after the third dose and had declined to a low level by six months. From a small number of participants we observed that natural infection or a fourth dose of vaccination generated similar antibody levels against ancestral virus, but infection generated higher antibody level against Omicron BA.2 than vaccination, suggesting a potential advantage in the breadth of antibody response from hybrid immunity.

**Conclusions:** While antibody levels against the ancestral strain remained robust at six months after the third dose, antibody levels against Omicron BA.2 had fallen to low levels suggesting the potential benefits of a fourth dose.
INTRODUCTION

Third doses of COVID-19 vaccination provide an important boost to immunity, reducing the risk of symptomatic infection [1, 2] and the risk of severe disease [2, 3]. Third doses have been particularly important for improving protection against variants. However, waning clinical protection particularly against Omicron was noted after receipt of third doses [4, 5], with fourth doses then providing additional protection [6, 7].

In recipients of two initial doses of inactivated COVID-19 vaccines, we and others have shown that a third “booster” dose of BNT162b2 (BioNTech/Pfizer/Fosun Pharma) confers a very strong antibody response both against the ancestral strain and the Omicron variant [8-10]. Here, we explore the persistence of antibody titers up to 6 months after a third dose of BNT162b2 in this regimen.

METHODS

Study design

We conducted an open-label single-arm trial to measure the antibody responses to a third dose of BNT162b2 in adults ≥30 years old who previously received two doses of an inactivated COVID-19 vaccine with the second inactivated vaccine dose at least 90 days prior to enrolment [8]. The BNT162b2 vaccine and the inactivated vaccine CoronaVac (Sinovac) were both approved for use in Hong Kong in early 2021, while an alternative inactivated vaccine BIBP (Sinopharm) has been available since early 2021 in mainland China and some other countries. We enrolled participants from October through December 2021. Participants were not eligible if they had received any other COVID-19 vaccination apart from the two doses of inactivated vaccination, if they had a history of laboratory-confirmed COVID-19 infection, if they met a contraindication for BNT162b2, were receiving immuno-modulatory
medications, or were females who were pregnant or intending to become pregnant in the
coming 3 months [8].

Each participant provided a serum sample at Day 0 prior to receipt of BNT162b2, and then
further serum samples on Day 28 (±7 days) and Day 182 (±30 days), with a final sample
planned on Day 365. Participants were provided with a gift voucher of HK$100 (US$13) at
the blood draws on Days 28, 182 and 365. We collected information at baseline on
demographics, health status including vaccinations received, and self-reported COVID-19
infection history. We updated this information at the Day 182 visit including information on
any infections that had occurred between Day 28 and Day 182.

Ethical approval
All participants provided written informed consent. The study was approved by the
Institutional Review Board of the University of Hong Kong. The study is registered on
Clinicaltrials.gov (NCT05057182).

Laboratory methods
We used a SARS-CoV-2 Spike receptor binding domain IgG enzyme-linked immunosorbent
assay (ELISA) for the ancestral strain as previously described [11]. 96-well ELISA plates
(Nunc MaxiSorp, Thermo Fisher Scientific) were coated overnight with 100 ng/well of the
purified recombinant RBD protein in PBS buffer. The plates were then blocked by 100 μl of
Chonblock blocking buffer (Chondrex Inc, Redmond, US) per well, and were incubated at
room temperature for 2 hours. Each serum sample was tested at a dilution of 1:100 in
Chonblock blocking buffer in duplicate. They were added and were incubated for 2 hours at
37°C. After extensive washing with PBS containing 0.1% Tween 20, horseradish peroxidase
(HRP)-conjugated goat anti-human IgG (1:5,000, GE Healthcare) was added and incubated for 1 hour at 37°C. The ELISA plates were then washed again with PBS containing 0.1% Tween 20. Subsequently, 100 μL of HRP substrate (Ncm TMB One; New Cell and Molecular Biotech Co. Ltd, Suzhou, China) was added into each well. After 15 minutes incubation, the reaction was stopped by adding 50 μL of 2 M H₂SO₄ solution and analyzed on a microplate reader at 450 nm wavelength. Optical density above 0.5 was counted as positive.

SARS-CoV-2 surrogate virus neutralization test (sVNT) kits (Cat. No.: L00847-A) were ordered from GenScript, Inc., NJ, USA. The tests were performed according to the manufacturer’s standard protocol. 10 times dilution were performed for samples, positive and negative controls. They were then mixed with equal volume of horseradish peroxidase (HRP) conjugated SARS-CoV-2 spike receptor binding domain (RBD) (6 ng). The mixture was incubated at 37°C for 30 min. After incubation, 100μl of the mixture was added to corresponding wells of the capture plate coated with ACE-2 receptor. The plate was sealed and incubated at 37°C for 30 min followed removing mixtures and washing with 1X wash solution four times. Residual liquid was emptied by tapping dry. 100μl of TMB solution was added to each well, the plate was wrapped with aluminium foil and incubated in the dark at room temperature for 15 minutes. The reaction was quenched by adding 50μl of stop solution. The absorbance was read at 450nm (OD₄₅₀) in an ELISA microplate reader. Percentage inhibition was calculated by (1-OD₄₅₀ value of sample/OD₄₅₀ value of negative control) multiplied by 100%.

The Plaque Reduction Neutralization Test (PRNT) was performed in duplicate using 24-well tissue culture plates (TPP Techno Plastic Products AG, Trasadingen, Switzerland) in a biosafety level 3 facility using Vero E6 TMRESS2 cells [12] for the ancestral strain and
Omicron BA.2 as previously described [13]. All sera were heat-inactivated at 56°C for 30 min before testing. Serial two-fold dilutions from 1:10 to 1:320 of each serum sample were incubated with 30–40 plaque-forming units of virus for 1 hour at 37°C and the mixture was added onto pre-formed cell monolayers. The culture plate was incubated for 1 hour at 37°C in a 5% CO₂ incubator. The virus-antibody inoculum was then discarded, and the cell monolayer was overlaid with 1% agarose in cell culture medium. The plates were fixed and stained after 3 days incubation. Antibody titres were defined as the reciprocal of the highest serum dilution that resulted in ≥50% reduction in the number of virus plaques (PRNT₅₀). The average plaque numbers were calculated from the duplicates. Virus back titrations, positive and negative control sera were included in every experiment.

Statistical analysis

We analyzed data on antibody titers measured by the assays listed above at Day 0, Day 28 and Day 182. We determined whether participants reported a laboratory-confirmed infection between Day 28 and Day 182, or had chosen to receive a fourth dose of a COVID-19 vaccine during the same period, and classified accordingly for analysis. We estimated group means for the ELISA and surrogate neutralizing percentages, and geometric mean titers for the live virus neutralization titers. We estimated the rate of waning in neutralizing antibody titers for those who were not infected and did not receive a fourth dose assuming an exponential rate of decline (constant decline on the logarithmic scale). Statistical analyses were conducted using R version 3.6.2 (R Foundation for Statistical Computing, Vienna, Austria).

RESULTS

We administered BNT162b2 as a third dose of COVID-19 vaccination to 314 participants between 18 October and 28 December 2021. We collected Day 28 samples from 312 (99%)
of these participants, and we collected Day 182 samples from 284 (90%) participants between
20 April and 1 June 2022. The median time between receipt of BNT162b2 and collection of
the Day 182 sample was 181 days (range 154, 210 days).

Further analyses focus on the 284 participants who provided a Day 182 sample. Among these
284 participants, 279 (98%) had received two initial doses of CoronaVac and the remainder
received two doses of BIBP. The median delay between the second dose of inactivated
vaccination and the third dose of BNT162b2 administered in our study was 205 days (range
94, 267 days). The median age was 53 years, 29% of participants were ≥60 years of age, 38%
were female, and 93 (32%) had a chronic medical condition.

Among the 284 participants, 42 (15%) reported a COVID-19 infection between receipt of the
third dose and collection of the Day 182 sample, and 21 (7.0%) reported receipt of a fourth
dose prior to collection of the Day 182 sample including one participant who was infected as
well as then receiving a fourth dose. The median delay from infection to collection of the Day
182 sample was 55 days (range 10, 85 days). The median delay from the fourth dose to
collection of the Day 182 sample was 19 days (range 7, 26) and 19 participants received
BNT162b2 as a fourth dose while two received CoronaVac.

The third dose of BNT162b2 led to substantial increases in ELISA (Figure 1A) and surrogate
virus neutralization levels (Figure 1B) at Day 28, which waned somewhat by Day 182 but
still remained substantially higher than the levels at Day 0. ELISA values at Day 182 were
statistically significantly higher in the small number of participants who were infected
(p<0.001, t-test) or received a fourth dose (p=0.005, t-test) prior to Day 182. The sVNT
responses were very high at Day 182 in all groups, but also statistically significantly higher in
the small number of participants who were infected (p=0.002, t-test) or received a fourth dose (p=0.032, t-test) prior to Day 182. There was no statistically significant difference in ELISA or sVNT levels by age at Day 182.

We measured PRNT$_{50}$ titers against the ancestral strain (Figure 1C) and Omicron BA.2 (Figure 1D) in a subset of 39 participants at Day 0, 28 and 182. In the statistical comparisons within this subset that follow we exclude (because of the small sample sizes) from Day 182 calculations the three infected participants and the two who received a fourth dose, although they are included in Figure 1 for completeness. At Day 28 and Day 182 the geometric mean PRNT$_{50}$ titers against the ancestral strain were 338 and 112, respectively. The corresponding geometric mean PRNT$_{50}$ titers against BA.2 were 55 and 14, respectively. There was no significant difference by age in PRNT$_{50}$ titers against the ancestral strain or BA.2 at Day 182. Assuming an exponential rate of waning from Day 28 to Day 182, we estimated that antibody titers would drop by half in 96 days for the ancestral strain and 79 days for BA.2.

Among the 42 infections, 30 (71%) occurred during the month of March 2022, with nine in February and three in April, when BA.2 predominated in the community. We did not find any statistically significant effects on the risk of laboratory-confirmed infection of the timing of third dose, age, sex, chronic conditions, or antibody measures at Day 28 (all p>0.05, proportional hazards regression).

**DISCUSSION**

We show durable antibody responses to the ancestral strain six months after the third dose of BNT162b2 (Figure 1), consistent with other studies that show a strong and sustained antibody response to a third dose of BNT162b2 after two doses of BNT162b2 [14, 15] or after two
doses of inactivated vaccination [16]. Antibody titers measured by sVNT against the ancestral strain were higher at 97% six months after the third dose of BNT162b2 (and two earlier doses of CoronaVac) than six months after either two doses of BNT162b2 or two doses of CoronaVac, when sVNT inhibition had fallen to 80% and 20% respectively in another study [17]. However, neutralizing titers to Omicron BA.2 only reached a moderate geometric mean titer of 55 after the third dose, above a threshold thought to provide some degree of protection against infection in this assay [13] but titers had fallen to below a geometric mean of 14 within six months, likely below the protective threshold (Figure 1D).

There is some evidence from observational studies that third doses can protect against symptomatic Omicron BA.2 infection [1, 2]. In a study of the effectiveness of two and three doses of COVID-19 vaccines in Hong Kong we found evidence suggestive of a moderate level of protection against mild infection [18]. The immune mechanisms contributing to that protection are not fully elucidated but neutralizing antibodies are likely to play a major role, while cellular immunity may also contribute [19]. Fourth doses did improve antibody levels against the ancestral strain (Figure 1) and likely also against BA.2. From a small number of participants we observed that natural infection or (fourth dose) vaccination after third dose BNT162b2 vaccination generated similar antibody levels against ancestral virus, but infection generated higher antibody level against Omicron BA.2 than vaccination, suggesting a potential advantage in the breadth of antibody response from hybrid immunity [20]. Further studies are needed to confirm this finding and to determine the optimal timing of fourth doses under different types of prior immunity.

Our study had a number of limitations. A large wave of Omicron BA.2 occurred in Hong Kong in February-April 2022 with more than 1 million confirmed cases (14% of the
population) and 9000 deaths (1.2 deaths per 1000 persons) [21]. Many infections likely were undocumented. While 15% of our cohort reported an infection, including some infections that may not have been documented in the official case count, some other participants may have had an unrecognized infection, biasing upwards the antibody titers at Day 182.

In conclusion, a third dose of BNT162b2 provided a strong and durable immune response in adults who had previously received two doses of inactivated COVID-19 vaccine. Further research is needed on the value of immunogenicity data (including cellular immunity measures as well as antibody levels) to predict the clinical effectiveness of booster doses against symptomatic disease and severe disease with Omicron subvariants.
ACKNOWLEDGEMENTS

We gratefully acknowledge colleagues including Zacary Chai, Sara Chaithai, Kelvin Kwan, Yvonne Ng, Teresa So and Eileen Yu for technical support in preparing and conducting this study; Anson Ho for setting up the database; Julie Au and Lilly Wang for administrative support; Hetti Cheung, Victoria Wong, Bobo Yeung at HKU Health System; Cindy Man and other colleagues at the HKU Community Vaccination Centres at Gleneagles Hospital; and all the study participants for facilitating the study.

FUNDING

This project was supported by the Theme-based Research Scheme T11-705/21-N of the Research Grants Council of the Hong Kong Special Administrative Region, China (BJC).

BJC is supported by a RGC Senior Research Fellow Scheme grant (HKU SRFS2021-7S03) from the Research Grants Council of the Hong Kong Special Administrative Region, China.

The funding bodies had no role in the design of the study, the collection, analysis, and interpretation of data, or writing of the manuscript.

AUTHOR CONTRIBUTIONS

All authors meet the ICMJE criteria for authorship. Each author’s contributions to the paper are listed below according to the CRediT model:

Conceptualization: BJC, GML, NHLL

Methodology: BJC, SMSC

Formal analysis: BJC, MM-S

Investigation: NYMA, KCKC, JKCL, LLHL

Funding acquisition: BJC

Project administration: BJC, SMSC, JSMP, NHLL
Supervision: BJC, SMSC, DKMI, LLMP, GML, JSMP, NHLL

Writing – original draft: BJC

Writing – review & editing: BJC, SMSC, MM-S, NYMA, KCKC, JKCL, LLHL, DKMI, LLMP, GML, JSMP, NHLL.

COMPETING INTERESTS

BJC consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Moderna, Pfizer, Roche and Sanofi Pasteur. BJC has received research funding from Fosun Pharma. The authors report no other potential conflicts of interest.
REFERENCES


FIGURE LEGEND

Figure 1. Antibody titers measured prior to receipt of a third dose of BNT162b2 (Day 0), and at Day 28 and Day 182 following that dose, using four assays. Samples collected at Day 182 were stratified by whether the participant had been infected or received a fourth dose between Day 28 and Day 182. Panel A: antibody titers measured by an ELISA assay for serum IgG against the receptor binding domain (RBD) of the spike protein of the ancestral strain, with X indicating the median level. Panel B: Responses to a surrogate virus neutralization test (sVNT) against the ancestral strain, with X indicating the median level. Panel C: Live virus plaque reduction neutralization test (PRNT) against ancestral strain with endpoints at 50% (PRNT_{50}) with X indicating the geometric mean titer in each group. Panel D: Live virus PRNT_{50} against the Omicron BA.2 subvariant, with X indicating the geometric mean titer in each group. In panels C and D, antibody titers measured at <10 are plotted at 5 on the y-axis.
A. **RBD ELISA IgG**

<table>
<thead>
<tr>
<th></th>
<th>Before 3rd dose (n=284)</th>
<th>After 3rd dose (n=284)</th>
<th>No infection, no 4th dose (n=76)</th>
<th>Infection (n=22)</th>
<th>4th dose (n=11)</th>
<th>Infection and 4th dose (n=0)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Day 0</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Day 28</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Day 182</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B. **Surrogate VNT**

<table>
<thead>
<tr>
<th></th>
<th>Before 3rd dose (n=284)</th>
<th>After 3rd dose (n=284)</th>
<th>No infection, no 4th dose (n=222)</th>
<th>Infection (n=41)</th>
<th>4th dose (n=20)</th>
<th>Infection and 4th dose (n=1)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Day 0</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Day 28</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Day 182</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C. **Ancestral strain PRNT**

<table>
<thead>
<tr>
<th></th>
<th>Before 3rd dose (n=39)</th>
<th>After 3rd dose (n=39)</th>
<th>No infection, no 4th dose (n=33)</th>
<th>Infection (n=3)</th>
<th>4th dose (n=3)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Day 0</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Day 28</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Day 182</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

D. **BA.2 PRNT**

<table>
<thead>
<tr>
<th></th>
<th>Before 3rd dose (n=39)</th>
<th>After 3rd dose (n=39)</th>
<th>No infection, no 4th dose (n=33)</th>
<th>Infection (n=3)</th>
<th>4th dose (n=3)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Day 0</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Day 28</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Day 182</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*This is a preprint and has not been peer-reviewed.*